Performance Suite was Evolent Health’s largest product and service line in fiscal 2025, bringing in $1.13B of $1.88B (60%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Performance Suite | $808.64M | $1.21B | $1.80B | $1.13B | |||||
| Platforms & Operations Services | — | — | — | — | |||||
| Administrative Services | $407.52M | $296.24M | $238.04M | $226.68M | |||||
| Specialty Technology & Services Suite | $51.90M | $296.37M | $338.31M | $353.23M | |||||
| Cases | $83.95M | $156.63M | $176.52M | $168.98M | |||||
| Premiums | — | — | — | — | |||||
| Transformation Services | — | — | — | — | |||||
| Intersegment Eliminations | — | — | — | — | |||||
| Total | $1.35B | $1.96B | $2.55B | $1.88B |
Evolent Health brought in $1.88B from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 26.6% from $2.55B in fiscal 2024. Performance Suite was the largest at $1.13B (60.1%), ahead of Specialty Technology & Services Suite at $353.23M (18.8%) and Administrative Services at $226.68M (12.1%). The remaining line, Cases, brought in $168.98M.
Compared with fiscal 2024, Specialty Technology & Services Suite grew fastest, up 4.4% to $353.23M, while Performance Suite fell the most, down 37.4% to $1.13B. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.35B to $1.88B, a compound annual growth rate of 11.5%. Performance Suite's share held steady at about 60.1%.
Medicaid was Evolent Health’s largest revenue line in fiscal 2025, bringing in $818.31M of $1.88B (44%).
| Customer | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Medicaid | $559.36M | $785.05M | $862.40M | $818.31M | |||
| Medicare | $458.41M | $708.85M | $1.05B | $464.24M | |||
| Commercial & Other | $334.24M | $469.99M | $646.42M | $593.68M | |||
| Total | $1.35B | $1.96B | $2.55B | $1.88B |
Evolent Health brought in $1.88B from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 26.6% from $2.55B in fiscal 2024. Medicaid was the largest at $818.31M (43.6%), ahead of Commercial & Other at $593.68M (31.6%) and Medicare at $464.24M (24.7%).
Compared with fiscal 2024, every revenue line above 2% of revenue shrank. Medicaid held up best, down 5.1% to $818.31M, and Medicare fell the most, down 55.6% to $464.24M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $1.35B to $1.88B, a compound annual growth rate of 11.5%. Medicaid's share of the total rose from 41.4% to 43.6%.
Evolent Health (EVH) reports its revenue by product and service and by customer. In fiscal 2025, Performance Suite was its largest product and service line, bringing in $1.13B (60.1% of the total), followed by Specialty Technology & Services Suite at $353.23M (18.8%).
Performance Suite was Evolent Health's largest product and service line in fiscal 2025, bringing in $1.13B, or 60.1% of the $1.88B total across its four product and service lines.
Medicaid was Evolent Health's largest revenue line in fiscal 2025, bringing in $818.31M, or 43.6% of the $1.88B total across its three revenue lines.
Among Evolent Health's product and service lines that make up at least 2% of revenue, Specialty Technology & Services Suite grew fastest in fiscal 2025, up 4.4% from $338.31M to $353.23M.
Every figure comes from Evolent Health's annual financial filings, as reported. Each line keeps the name Evolent Health gives it, and years follow its fiscal calendar.
Evolent Health's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.